These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2007317)

  • 21. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
    Salih IS; Thanacoody RH; McKay GA; Thomas SH
    Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.
    Eap CB; Guentert TW; Schãublin-Loidl M; Stabl M; Koeb L; Powell K; Baumann P
    Clin Pharmacol Ther; 1996 Mar; 59(3):322-31. PubMed ID: 8653995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
    LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
    Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.
    Shvartsburd A; Nwokeafor V; Smith RC
    Psychopharmacology (Berl); 1984; 82(1-2):55-61. PubMed ID: 6420831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.
    Steiner E; Bertilsson L; Säwe J; Bertling I; Sjöqvist F
    Clin Pharmacol Ther; 1988 Oct; 44(4):431-5. PubMed ID: 3168394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
    Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
    Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulphoxide metabolites of thioridazine in man.
    Papadopoulos AS; Crammer JL
    Xenobiotica; 1986 Dec; 16(12):1097-107. PubMed ID: 3798957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.
    Greendyke RM; Kanter DR
    J Clin Psychopharmacol; 1987 Jun; 7(3):178-82. PubMed ID: 3597804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a metabolite of thioridazine and mesoridazine from human plasma.
    Gruenke LD; Craig JC
    Res Commun Chem Pathol Pharmacol; 1975 Feb; 10(2):221-5. PubMed ID: 1162173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum concentration and protein binding of thioridazine and its metabolites in patients with chronic alcoholism.
    Axelsson R; Mårtensson E; Alling C
    Eur J Clin Pharmacol; 1982 Oct; 23(4):359-63. PubMed ID: 7173306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.
    Steiner E; Iselius L; Alván G; Lindsten J; Sjöqvist F
    Clin Pharmacol Ther; 1985 Oct; 38(4):394-401. PubMed ID: 4042522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous assay of thioridazine and its major metabolites in plasma at single dosage levels with a novel report of two ring sulfoxides of thioridazine.
    Wells CE; Juenge EC; Furman WB
    J Pharm Sci; 1983 Jun; 72(6):622-5. PubMed ID: 6875822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
    Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
    Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of thioridazine in blood and urine.
    Ng CH; Crammer JL
    Br J Clin Pharmacol; 1977 Apr; 4(2):173-83. PubMed ID: 16633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type.
    Meyer JW; Woggon B; Baumann P; Meyer UA
    Eur J Clin Pharmacol; 1990; 39(6):613-4. PubMed ID: 2095351
    [No Abstract]   [Full Text] [Related]  

  • 37. Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs.
    Lin G; Chu KW; Damani LA; Hawes EM; Midha KK
    J Pharm Biomed Anal; 1996 Apr; 14(6):727-38. PubMed ID: 8807548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
    Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
    J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partitioning of thioridazine and mesoridazine in human blood fractions.
    Dinovo EC; Pollak H; Gottschalk LA
    Methods Find Exp Clin Pharmacol; 1984 Mar; 6(3):143-6. PubMed ID: 6748818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
    Lennard MS; Silas JH; Freestone S; Trevethick J
    Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.